Generate Biomedicines (NASDAQ:GENB) Issues Quarterly Earnings Results

Generate Biomedicines (NASDAQ:GENB) released its earnings results on Thursday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04), FiscalAI reports. The business had revenue of $6.31 million for the quarter.

Generate Biomedicines Price Performance

NASDAQ GENB traded down $0.60 on Thursday, hitting $13.89. 842,934 shares of the stock were exchanged, compared to its average volume of 489,564. The business has a fifty day simple moving average of $14.42. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $18.18. The stock has a market capitalization of $1.78 billion and a P/E ratio of -12.98.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GENB shares. Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Morgan Stanley lifted their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Finally, HC Wainwright raised their price target on Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Generate Biomedicines stock. Bank of New York Mellon Corp bought a new stake in Generate Biomedicines Inc (NASDAQ:GENB) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 57,326 shares of the company’s stock, valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.